BCL2 and B-cell chronic lymphocytic leukemia: Our data demonstrate that BCL-2 could be an important marker to distinguish patient populations with profound defects in T cell functions and highlight the possibility that BCL-2 inhibitors can restore T cell functions in patients with CLL.